TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02523859
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic drug used for anesthesia
Study: NCT02523859
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Benzodiazepine being developed for sedation and anesthesia.
Study: NCT01610037
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 µg will be supplied as capsules in blister packs for once daily inhalation using the HandiHaler SDDPI
Study: NCT01901419
Drug: Nitroglycerin infusion
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin infusion during rewarming
Study: NCT00570375
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg, PO, QD beginning day 1 week 1. Patients will receive treatment for 16 weeks as long as there is no evidence of disease progression. In no response is noted after 16 weeks of treatment, patients will be taken off the study. Patients achieving response (HI, CR, or PR) will continue on treatment until evidence of disease progression or relapse.
Study: NCT01404611
Drug: DF277
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ear drops
Study: NCT02868580
Drug: Triumeq
Normalized name: Triumeq
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Triumeq, a combination of dolutegravir, abacavir and lamivudine is an anti-retroviral therapy indicated for people with HIV-1 infection.
Study: NCT01241487
Drug: valsartan/amlodipine
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 160/10 mg
Study: NCT00979550
Drug: Imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: commercially available topical antiviral drug
Study: NCT03122132
Drug: ombitasvir/paritaprevir/ritonavir 8 weeks
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ ritonavir 8 weeks
Study: NCT03122132
Drug: dasabuvir 8 weeks
Normalized name: Dasabuvir
DrugBank: Dasabuvir (DB09183)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Spanish cohort with HCV treated in real practice with dasabuvir 8 weeks
Study: NCT02377609
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00550589
Drug: cidofovir
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.0% topical cream self-applied once daily for 5 consecutive days, with no treatment for the remaining 9 days (a treatment cycle). Subjects will receive up to 6 cycles of treatment.
Study: NCT00324974
Drug: Lansoprazole microgranules suspension
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole microgranules 0.2-0.3 mg/kg/day suspension, orally, once daily for up to 28 days for infants less than 10 weeks;~Lansoprazole microgranules 1.0-1.5 mg/kg/day suspension, orally, once daily for up to 28 days for infants greater than 10 weeks.
Study: NCT01287793
Drug: moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet, 400 mg, single dose
Study: NCT01287793
Drug: 100 mL 0.9% Sodium Chloride intravenous
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous fluid, 100 mL, single dose
Study: NCT01060891
Drug: colimycin
Normalized name: Colimycin
DrugBank: Colistin (DB00803)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00810069
Drug: Duloxetine Hydrochloride
Normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flexible dose of 60 or 120 mg daily
Study: NCT00810069
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg in both Early and Delayed Intervention. Flexible dose of 10 to 20 mg daily in Delayed Intervention.
Study: NCT02812693
Drug: Imatinib Mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT01088984
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03079505
Drug: Dasatinib 100 MG [Sprycel]
Normalized name: dasatinib 100 MG [Sprycel]
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib (Sprycel) 100 milligram, once-daily (QD) will be given to 25 patients orally
Study: NCT03619447
Drug: ESP block group
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: USG guided Erector spinae block (ESP) will perform bilaterally.
Study: NCT02344264
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml.
Study: NCT02344264
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).~Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml.
Study: NCT03069534
Drug: RhIL-2
Normalized name: rhIL-15
DrugBank: Interleukin-15, human recombinant (DB17467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RhIL-2 treatment intervention was consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotharapy. rhIL-2 (500,000 U/m)regimen was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7.
Study: NCT00524251
Drug: esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03079505
Drug: Nilotinib 150mg oral capsule [Tasigna]
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib (Tasigna) 300 milligram, twice-daily (BID) will be given to 25 patients orally
Study: NCT02517957
Drug: Furoic acid loperamide hydrochloride cream
Normalized name: Loperamide Hydrochloride
DrugBank: Loperamide (DB00836)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Apply to lesion area without erosion, drainage, 1 times a day, continuous use 1 week after according to disease reduction or withdrawal, the longest do not exceed 4 weeks. Pure dry area or no skin itching area should not be applied.
Study: NCT02517957
Drug: 3% boric acid solution
DrugBank: Boric acid (DB11326)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3% boric acid solution is suitable for the erosion seepage skin, can open intermittent shi fu, 5-10 min each time, 2 times daily or several times.
Study: NCT02517957
Drug: Zine oxide
Normalized name: Ferrosoferric Oxide
DrugBank: Ferric sulfate (DB11171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In wet apply the break to zinc oxide preparation for external use only, when erosion seepage control is disabled in skin lesions.
Study: NCT01006980
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 960 mg (as 240 mg tables) orally twice daily
Study: NCT01006980
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg/m2 intravenously every 3 weeks
Study: NCT00128102
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat 100 mg oral capsules
Study: NCT03232580
Drug: rhAnnexin V-128
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients received a single i.v injection of 99mTc-rhAnnexin V-128 at Day 0.
Study: NCT01202903
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.
Study: NCT02265289
Drug: Lefradafiban
Normalized name: Lefradafiban
DrugBank: Lefradafiban (DB04863)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02265289
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00237731
Drug: morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine 0.05
Study: NCT00237731
Drug: morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine 0.10
Study: NCT02435303
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01581177
Drug: Albuterol DPI 25 mcg/inh
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol DPI with 25 mcg Albuterol/inhalation
Study: NCT01581177
Drug: Albuterol DPI 90 mcg/inh
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol DPI with 90 mcg Albuterol/inhalation
Study: NCT01581177
Drug: Albuterol MDI 90 mcg/inh
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol MDI with 90 mcg Albtuerol/inhalation
Study: NCT02897050
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75mg/m2, iv, d1 or 100mg/m2, iv, d1
Study: NCT02897050
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin 100mg/m2, iv, d1
Study: NCT00678613
Drug: Probiotics and Norfloxacin
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder.It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs will be given for one year or till the end points of the study.
Study: NCT02420951
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of local anesthetic immediately prior to catheter removal, 24 hours postop.
Study: NCT04542213
Drug: Linagliptin tablet
Normalized name: Linagliptin Tablets
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Linagliptin 5mg once daily plus a basal-bolus insulin scheme
Study: NCT01175538
Drug: Lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the Gp-L group, patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day
Study: NCT04542213
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal-bolus insulin scheme
Study: NCT01175538
Drug: Lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: lactulose will be used in 30-60ml/day
Study: NCT00442234
Drug: Monteplase
Normalized name: Monteplase
DrugBank: Monteplase (DB12726)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01396889
Drug: Echinacea
Normalized name: Echinacea
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old
Study: NCT01342341
Drug: Parafon Forte
Normalized name: Parafon Forte DSC
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Parafon Forte administered at study visit~Other: Placebo administered at study visit
Study: NCT00419042
Drug: TARCEVA
Normalized name: Tarceva
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tarceva (150 mg) is a pill you take once a day -- every day -- to help treat non-small cell lung cancer.
Study: NCT00419042
Drug: Gemzar
Normalized name: Gemzar
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GEMZAR by mixing it into a solution and giving it through a needle into a vein-called intravenous infusion (IV). This will take about 30 minutes
Study: NCT02541864
Drug: Bismuth quadruple therapy
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg bid for 14 days, bismuth subcitrate 120 mg qid for 14 days, tetracycline 500 mg qid for 14 days, metronidazole 250 mg qid for 14 days
Study: NCT01526564
Drug: Acetylcarnitine
Normalized name: Acetylcarnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of enteric-coated tablets with warm water at half an hour after meals, 1g (2 tablets) each time, 3 times a day, and the interval at or \>4 hours for 8 weeks
Study: NCT01531673
Drug: VX-661
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01531673
Drug: Ivacaftor
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01531673
Drug: Placebo matched to ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04601753
Drug: Oral Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study: NCT02880410
Drug: Radiation therapy and temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Radiation therapy and temozolomide
Study: NCT02084563
Drug: Autologous Stem Cell Transplantation
Normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:~* Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4~* Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2
Study: NCT02084563
Drug: Allogeneic Stem Cell Transplantation
Normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with intermediate-/high-risk AML~Conditioning regimen:~* Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4~* Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2 or Fludarabine 40 mg/m2 IV once daily days -7 to -4
Study: NCT02084563
Drug: Low Dose Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy for patients with AML who are not fit for intensive chemotherapy:~* Cytarabine 60 mg/m2 subcutaneous (SQ) bid days 1-5 (until CR or maximum 4 cycles)~* Cytarabine 40 mg/m2 SQ bid days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)
Study: NCT02084563
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy for patients with AML who are not fit for intensive chemotherapy:~* Decitabine 20 mg/m2 IV once daily days 1-10 (until CR or maximum 4 cycles)~* Decitabine 20 mg/m2 IV once daily days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)
Study: NCT01244932
Drug: bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be given bupivacaine 0.5% in different doses (up-down study).
Study: NCT04196491
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepleting Chemotherapy
Study: NCT04196491
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance Therapy
Study: NCT03245853
Drug: Riboflavin 5'-Phosphate
Normalized name: RIBOFLAVIN 5'-PHOSPHATE
DrugBank: Flavin mononucleotide (DB03247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photrexa (riboflavin 5'-phosphate ophthalmic solution) 0.146%, is a yellow sterile buffered solution containing 1.46 mg/mL riboflavin 5'-phosphate, The pH of the solution is approximately 7.1 and the osmolarity is 157-177 mOsm/kg. Each 1 mL of the solution contains 1.53 mg of riboflavin 5'-phosphate sodium (equivilant to 1.20 mg \[0.12%\] riboflavin). Riboflavin 5'-phosphate sodium USP is a mixture of the sodium salts of riboflavin, riboflavin monophosphates, and riboflavin diphosphates. The inactive ingredients are dibasic sodium phosphate, monbasic sodium phosphate, sodium chloride, and water for injection.
Study: NCT00426764
Drug: Romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-day cycle.
Study: NCT02404610
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03812939
Drug: Octreotide
Normalized name: Octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 6-12 monthly injections every 28 (+/- 3) days.
Study: NCT00234026
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00532532
Drug: tolperisone HCl
Normalized name: tolperisone HCl
DrugBank: Tolperisone (DB06264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
Study: NCT00532532
Drug: tolperisone HCl
Normalized name: tolperisone HCl
DrugBank: Tolperisone (DB06264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
Study: NCT00532532
Drug: tolperisone HCl
Normalized name: tolperisone HCl
DrugBank: Tolperisone (DB06264)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
Study: NCT03638960
Drug: Bupivacaine liposome
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigators will perform an ultrasound-guided interscalene peripheral nerve block with either liposomal bupivacaine prior to the patient receiving surgery.
Study: NCT03638960
Drug: Bupivacaine Hydrochloride
Normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigators will perform an ultrasound-guided interscalene peripheral nerve block with either plain bupivacaine prior to the patient receiving surgery.
Study: NCT03113968
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine is a medication that is used as a short acting anesthetic in pediatric and adult medicine. Subanesthetic (low) doses will be given to patients via infusion in order to assess whether it helps with depression symptoms in patients who have not responded to antidepressant therapy. Ketamine is not FDA approved for this indication and its effectiveness in treatment resistant depression has not been proven. Prior studies have indicated that subanesthetic doses of ketamine may be helpful for treatment resistant depression.
Study: NCT00000444
Drug: nicotine replacement patch
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01590901
Drug: Probucol
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250mg (1 tablet) bid. p.o for 14 consecutive days
Study: NCT02081443
Drug: Ticagrelor 180mg
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
Study: NCT02081443
Drug: Ticagrelor 90mg
Normalized name: TICAGRELOR 90MG TAB
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
Study: NCT02931786
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol, midazolam and atropine administration via intravenous cannula.
Study: NCT02931786
Drug: Ketamine propofol mixture
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of ketamine propofol mixture, midazolam and atropine via intravenous cannula
Study: NCT01918917
Drug: Levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intraarticular
Study: NCT01918917
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intraarticular 1 ml (100 mcg)
Study: NCT01918917
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenously, patient-controlled analgesia
Study: NCT00954265
Drug: 10000 IU urinary HCG
Normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ovulation triggering
Study: NCT04157088
Drug: Darolutamide (Nubeqa, BAY1841788)
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 600mg, twice daily